Cellectis (CLLS) Change in Working Capital (2015 - 2026)
Cellectis' (CLLS) quarterly Change in Working Capital came in at -$19.5 million in Q1 2026, down 195.99% year-on-year from $20.3 million in Q1 2025, and down 151.97% quarter-over-quarter from $37.5 million in Q4 2025.
Cellectis (CLLS) Change in Working Capital (2015 - 2026) Analysis & Trends
Cellectis' Change in Working Capital history runs 12 years deep, the most recent figure standing at -$19.5 million for Q1 2026.
- On a quarterly basis, Change in Working Capital fell 195.99% year-over-year to -$19.5 million in Q1 2026; TTM through Mar 2026 was $28.7 million, a 165.23% increase from a year earlier, with the FY2025 full-year figure at $41.6 million, up 177.5% from the prior year.
- Change in Working Capital retreated to -$19.5 million in Q1 2026 per CLLS's latest filing, from $37.5 million in the prior quarter.
- Across five years, Change in Working Capital topped out at $70.1 million in Q4 2022 and bottomed at -$22.2 million in Q1 2022.
- The 5-year median for Change in Working Capital is -$16.0 million (2023), against an average of -$4.4 million.
- Across the five-year window, Change in Working Capital sank 606.61% in 2024 and jumped 426.92% in 2025, its largest moves.
- Year by year, Change in Working Capital stood at $70.1 million in 2022, then sank by 94.22% to $4.1 million in 2023, then sank by 606.61% to -$20.5 million in 2024, then soared by 282.66% to $37.5 million in 2025, then tumbled by 151.97% to -$19.5 million in 2026.
- Per Business Quant, the three latest CLLS Change in Working Capital figures stand at -$19.5 million (Q1 2026), $37.5 million (Q4 2025), and $17.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -19.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.50 Mn |
| Mar 31, 2026 | -19.50 Mn |
| Dec 31, 2025 | 37.52 Mn |
| Dec 31, 2025 | 37.52 Mn |
| Sep 30, 2025 | 16.96 Mn |
| Sep 30, 2025 | 16.96 Mn |
| Jun 30, 2025 | -6.31 Mn |
| Jun 30, 2025 | -6.31 Mn |
| Mar 31, 2025 | -6.59 Mn |
| Mar 31, 2025 | -6.59 Mn |
| Dec 31, 2024 | -20.54 Mn |
| Dec 31, 2024 | -20.54 Mn |
| Sep 30, 2024 | -5.19 Mn |
| Sep 30, 2024 | -5.19 Mn |
| Jun 30, 2024 | -11.65 Mn |
| Jun 30, 2024 | -11.65 Mn |
| Mar 31, 2024 | -16.29 Mn |
| Mar 31, 2024 | -16.29 Mn |
| Dec 31, 2023 | 4.06 Mn |
| Dec 31, 2023 | 4.06 Mn |